Comparative, pivotal, phase III trial of spray-on transdermally delivered testosterone [Testagen TDS] versus gel testosterone for male hormone replacement
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2016
Price : $35 *
At a glance
- Drugs Testosterone (Primary) ; Testosterone (Primary)
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- 19 Apr 2016 According to a TransDermal Delivery Solutions media release, the Company has received regulatory approval for pivotal clinical trials of Testagen HypoSpray from the British National Health Services and the Medicine and Health Products Review Authority. The company expects to initiate this trial in next few weeks.
- 26 Aug 2013 New trial record
- 22 Aug 2013 Planned initiation date changed from 1 Mar 2009 to 1 Dec 2013, based on information in a Transdermal Delivery Solutions Corporation media release.